Back to top
more

Teva Pharmaceutical Industries (TEVA)

(Delayed Data from NYSE)

$18.45 USD

18.45
7,100,133

+0.01 (0.05%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $18.45 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 20% (49 out of 250)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Mallinckrodt to Divest Contract Manufacturing Unit, Stock Up

by Zacks Equity Research

Mallinckrodt's (MNK) shares gain as it agrees to sell its contract manufacturing unit to raise cash to settle liabilities from various opioid litigations.

Mallinckrodt (MNK) to Resolve Opioid Cases with Ohio Counties

by Zacks Equity Research

Mallinckrodt (MNK) reaches a settlement in principle with a couple of Ohio counties for opioid litigation.

Novartis Announces Positive Long-Term Data on Migraine Drug

by Zacks Equity Research

Novartis' (NVS) migraine drug Aimovig is effective and safe in treating patients with episodic migraine in a long-term study.

Mallinckrodt Mulls Bankruptcy Ahead of Major Opioid Litigation

by Zacks Equity Research

Mallinckrodt (MNK) plunges as the risk of filing for bankruptcy rises ahead of the multi-district opioid litigation scheduled next month.

Allergan Settles Ahead of Multi-District Opioid Litigation

by Zacks Equity Research

Allergan (AGN) settles with two counties of Ohio for $5 million related to the upcoming multidistrict litigation for opioid-based drug abuse.

Novartis' (NVS) MS Drug Achieves Goals in Late-Stage Studies

by Zacks Equity Research

Novartis (NVS) MS drug meets primary and secondary endpoints in late-stage studies.

Indrajit Bandyopadhyay headshot

Will Opioid Litigation Take its Toll on Pharma Companies?

by Indrajit Bandyopadhyay

Thousands of pending opioid-abuse lawsuits against several pharma companies come into limelight after the Oklahoma ruling against J&J. Let's see what's in store for these companies.

Christopher Vargas headshot

J&J (JNJ) Loses Landmark Opioid Case: What's Next for Pharmaceuticals?

by Christopher Vargas

An Oklahoma judge ruled on Monday that large cap pharmaceutical company Johnson & Johnson (JNJ) would have to pay $572 million to the state.

AstraZeneca's Fasenra Gets Orphan Drug Status for New Disease

by Zacks Equity Research

AstraZeneca's (AZN) Fasenra gets Orphan Drug status for eosinophilic oesophagitis (EoE). A phase III COPD study on Breztri Aerosphere meets primary endpoint.

J&J Up Despite $572M Fine in Oklahoma Opioid Abuse Case

by Zacks Equity Research

A court ordered J&J (JNJ) to pay $527 million in the Oklahoma litigation related to abuse of its opioid-based drugs. The company is facing similar litigation in multiple states.

Case-Shiller Index Nudges Up

by Zacks Equity Research

Case-Shiller Index Nudges Up

Mark Vickery headshot

J&J to Pay $572M in Opioid Case; Plus Case-Shiller Home Price Read

by Mark Vickery

Johnson & Johnson (JNJ) now owes $572 million, as per the judge in this case, which pits J&J responsible for rampant opioid use.

J&J's (JNJ) Opioid Lawsuit Verdict in Oklahoma Due Next Week

by Zacks Equity Research

J&J (JNJ) is facing several litigation in multiple states related to abuse of its opioid-based drugs. A ruling is expected on Aug 26 in a trial filed by the state of Oklahoma.

Kinjel Shah headshot

Pharma Stock Roundup: ABBV's Rinvoq Gets FDA Nod, BAYRY to Sell Animal Health Unit

by Kinjel Shah

FDA approves AbbVie's (ABBV) upadacitinib to be marketed as Rinvoq. Bayer (BAYRY) is set to divest its Animal Health unit to Elanco for $7.6 billion in a cash-and-stock deal.

BeiGene's NDA for Zanubrutinib Gets Priority Review From FDA

by Zacks Equity Research

The FDA grants priority review to BeiGene's (BGNE) NDA seeking approval for zanubrutinib as a treatment for mantle cell lymphoma.

Mallinckrodt (MNK) Stock Down 70.8% YTD on Numerous Lawsuits

by Zacks Equity Research

Mallinckrodt (MNK) crashes 70.8% in the year so far due to various lawsuits and litigations.

Endo Up on Settlement of a Few Cases Related to Opioid Drugs

by Zacks Equity Research

Endo (ENDP) finally has some good news for investors with the settlement of a few cases in Ohio related to opioid medications.

Teva Launches Generic Version of Mylan's EpiPen for KIds

by Zacks Equity Research

Teva (TEVA) launches generic version of Mylan's (MYL) popular EpiPen Jr allergy treatment at a price of $300 for a pack of two.

Should Value Investors Pick Teva Pharmaceutical (TEVA) Now?

by Zacks Equity Research

Let's see if Teva Pharmaceutical (TEVA) stock is a good choice for value-oriented investors right now from multiple angles.

Jazz (JAZZ) Acquires Cavion, Adds Movement Disorder Candidate

by Zacks Equity Research

Jazz (JAZZ) acquires privately-held Cavion for a total consideration of $312.5 million including an upfront payment of $52.5 million and $260 million in potential clinical, regulatory and commercial milestones.

BioDelivery (BDSI) Earnings & Sales Beat Estimates in Q2

by Zacks Equity Research

BioDelivery (BDSI) reports earnings against expectations of loss in Q2 and raises guidance for 2019.

Teva (TEVA) Q2 Earnings, Sales Top Estimates, CFO Steps Down

by Zacks Equity Research

Teva Pharmaceutical (TEVA) posts better-than-expected results. However, earnings and sales decline year over year.

Kinjel Shah headshot

Teva (TEVA) Beats Q2 Earnings & Sales Estimates, Shares Rise

by Kinjel Shah

Teva Pharmaceutical (TEVA) posts better-than-expected results. Shares rise in pre-market trading.

Cronos (CRON) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Investors will focus on Cronos' (CRON) regular top and bottom-line numbers along with its pipeline progress when it reports second-quarter results.

Will Cost Control Help Teva (TEVA) Beat on Q2 Earnings?

by Zacks Equity Research

Pricing erosion in U.S. generics market and rapid erosion in sales of Copaxone are likely to hurt Teva's (TEVA) sales in Q2.